Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines

Bibliography

• WANG RF: Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol. Rev. (2002) 188:65-80.
   PubMed Web of Science ®Google Scholar
• SETTE A, FIKES J: Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr. Opin. Immunol. (2003) 15:461-470.
   PubMed Web of Science ®Google Scholar
• HANSON HL, KANG SS, NORIAN LA, MATSUI K, O’MARA LA, ALLEN PM: CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors. J. Immunol. (2004) 172:4215-4224.
   PubMed Web of Science ®Google Scholar
• WONG R, LAU R, CHANG J et al.: Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin. Cancer Res. (2004) 10:5004-5013.
   PubMed Web of Science ®Google Scholar
• HUNG K, HAYASHI R, LAFOND-WALKER A, LOWENSTEIN C, PARDOLL D, LEVITSKY H: The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. (1998) 188:2357-2368.
   PubMed Web of Science ®Google Scholar
• SURMAN DR, DUDLEY ME, OVERWIJK WW, RESTIFO NP: Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J. Immunol. (2000) 164:562-565.
   PubMed Web of Science ®Google Scholar
• WELSH RM, SELIN LK, SZOMOLANYI-TSUDA E: Immunological memory to viral infections. Annu. Rev. Immunol. (2004) 22:711-743.
   Web of Science ®Google Scholar
• ADAMS S, HUMPHREYS RE: Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur. J. Immunol. (1995) 25:1693-1702.
   PubMed Web of Science ®Google Scholar
• ADAMS S, ALBERICIO F, ALSINA J, SMITH ER, HUMPHREYS RE: Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules. Arzneimittelforschung (1997) 47:1069-1077.
   PubMed Web of Science ®Google Scholar
• XU M, JACKSON R, ADAMS S, HUMPHREYS RE: Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1. Arzneimittelforschung (1999) 49:791-799.
   PubMed Web of Science ®Google Scholar
• XU M, LI J, GULFO JV, VON HOFE E, HUMPHREYS RE: MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases. Scand J. Immunol. (2001) 54:39-44.
   PubMed Web of Science ®Google Scholar
• HUMPHREYS RE, ADAMS S, KOLDZIC G, NEDELESCU B, VON HOFE E, XU M: Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine (2000) 18:2693-2697.
   PubMed Web of Science ®Google Scholar
• GILLOGLY ME, KALLINTERIS NL, XU M, GULFO JV, HUMPHREYS RE, MURRAY JL: Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol. Immunother. (2004) 53:490-496.
   PubMed Web of Science ®Google Scholar
• KALLINTERIS NL, LU X, WU S et al.: Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine (2003) 21:4128-4132.
   PubMed Web of Science ®Google Scholar
• KALLINTERIS NL, WU S, LU X, VON HOFE E, HUMPHREYS RE, XU M: Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies. Vaccine (2005) 23:2336-2338.
   PubMed Web of Science ®Google Scholar
• KALLINTERIS NL, WU S, LU X, HUMPHREYS RE, VON HOFE E, XU M: Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope. J. Immunother. (2005) 28:352-358.
   PubMed Web of Science ®Google Scholar
• AHLERS JD, TAKESHITA T, PENDLETON CD, BERZOFSKY JA: Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc. Natl. Acad. Sci. USA (1997) 94:10856-10861.
   Google Scholar
• SMITH CM, WILSON NS, WAITHMAN J et al.: Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat. Immunol. (2004) 5:1143-1148.
   PubMed Web of Science ®Google Scholar
• RIDGE JP, DI ROSA F, MATZINGER P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 393:474-478.
   PubMed Web of Science ®Google Scholar
• BERTOLINO P, RABOURDIN-COMBE C: The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells. Crit. Rev. Immunol. (1996) 16:359-379.
   PubMed Web of Science ®Google Scholar
• BODMER H, VIVILLE S, BENOIST C, MATHIS D: Diversity of endogenous epitopes bound to MHC class II molecules limited by invariant chain. Science (1994) 263:1284-1286.
   PubMed Web of Science ®Google Scholar
• XU M, CAPRARO GA, DAIBATA M, REYES VE, HUMPHREYS RE: Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern. Mol. Immunol. (1994) 31:723-731.
   PubMed Web of Science ®Google Scholar
• DAIBATA M, XU M, HUMPHREYS RE, REYES VE: More efficient peptide binding to MHC class II molecules during cathepsin B digestion of Ii than after Ii release. Mol. Immunol. (1994) 31:255-260.
   PubMed Web of Science ®Google Scholar
• REYES VE, DAIBATA M, ESPEJO R, HUMPHREYS RE: Invariant chain dissociation from class II MHC is a catalyst for foreign peptide binding. Ann. NY Acad. Sci. (1994) 730:338-341.
   PubMed Web of Science ®Google Scholar
• BAKKE O, DOBBERSTEIN B: MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell (1990) 63:707-716.
   PubMed Web of Science ®Google Scholar
• LAMB CA, CRESSWELL P: Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes. J. Immunol. (1992) 148:3478-3482.
   PubMed Web of Science ®Google Scholar
• BLUM JS, CRESSWELL P: Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc. Natl. Acad. Sci. USA (1988) 85:3975-3979.
   Google Scholar
• NGUYEN QV, KNAPP W, HUMPHREYS RE: Inhibition by leupeptin and antipain of the intracellular proteolysis of Ii. Hum. Immunol. (1989) 24:153-163.
   PubMed Web of Science ®Google Scholar
• SHI GP, BRYANT RA, RIESE R et al.: Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J. Exp. Med. (2000) 191:1177-1186.
   PubMed Web of Science ®Google Scholar
• RIESE RJ, WOLF PR, BROMME D et al.: Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity (1996) 4:357-366.
   PubMed Web of Science ®Google Scholar
• HILTBOLD EM, ROCHE PA: Trafficking of MHC class II molecules in the late secretory pathway. Curr. Opin. Immunol. (2002) 14:30-35.
   PubMed Web of Science ®Google Scholar
• RIBERDY JM, NEWCOMB JR, SURMAN MJ, BARBOSA JA, CRESSWELL P: HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature (1992) 360:474-477.
   PubMed Web of Science ®Google Scholar
• GAUTAM AM, PEARSON C, QUINN V, MCDEVITT HO, MILBURN PJ: Binding of an invariant-chain peptide, CLIP, to I-A major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA (1995) 92:335-339.
   Google Scholar
• ROMAGNOLI P, GERMAIN RN: The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J. Exp. Med. (1994) 180:1107-1113.
   PubMed Web of Science ®Google Scholar
• MORRIS P, SHAMAN J, ATTAYA M et al.: An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature (1994) 368:551-554.
   PubMed Web of Science ®Google Scholar
• DENZIN LK, CRESSWELL P: HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell (1995) 82:155-165.
   PubMed Web of Science ®Google Scholar
• KNUTSON KL, DISIS ML: Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. (2005) 54(8):721-728.
   PubMed Web of Science ®Google Scholar
• ROCHA B, TANCHOT C: Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses. Curr. Opin. Immunol. (2004) 16:259-263.
   PubMed Web of Science ®Google Scholar
• JANSSEN EM, DROIN NM, LEMMENS EE et al.: CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature (2005) 434:88-93.
   PubMed Web of Science ®Google Scholar
• DISSANAYAKE SK, THOMPSON JA, BOSCH JJ et al.: Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res. (2004) 64:1867-1874.
   PubMed Web of Science ®Google Scholar
• OSSENDORP F, MENGEDE E, CAMPS M, FILIUS R, MELIEF CJ: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. (1998) 187:693-702.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298:850-854.
   PubMed Web of Science ®Google Scholar
• ROBBINS PF, EL-GAMIL M, LI YF, ZENG G, DUDLEY M, ROSENBERG SA: Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J. Immunol. (2002) 169:6036-6047.
   PubMed Web of Science ®Google Scholar
• GAO FG, KHAMMANIVONG V, LIU WJ, LEGGATT GR, FRAZER IH, FERNANDO GJ: Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res. (2002) 62:6438-6441.
   PubMed Web of Science ®Google Scholar
• YU P, SPIOTTO MT, LEE Y, SCHREIBER H, FU YX: Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J. Exp. Med. (2003) 197:985-995.
   PubMed Web of Science ®Google Scholar
• ANTONY PA, PICCIRILLO CA, AKPINARLI A et al.: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. (2005) 174:2591-2601.
   PubMed Web of Science ®Google Scholar
• MANDIC M, CASTELLI F, JANJIC B et al.: One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J. Immunol. (2005) 174:1751-1759.
   PubMed Web of Science ®Google Scholar
• LU J, HIGASHIMOTO Y, APPELLA E, CELIS E: Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J. Immunol. (2004) 172:4575-4582.
   PubMed Web of Science ®Google Scholar
• SLAGER EH, VAN DER MINNE CE, KRUSE M, KRUEGER DD, GRIFFIOEN M, OSANTO S: Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes. J. Immunol. (2004) 172:5095-5102.
   PubMed Web of Science ®Google Scholar
• KAMAL SM, RASENACK JW, BIANCHI L et al.: Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology (2001) 121:646-656.
   PubMed Web of Science ®Google Scholar
• PATKE DS, FARBER DL: Modulation of memory CD4 T cell function and survival potential by altering the strength of the recall stimulus. J. Immunol. (2005) 174:5433-5443.
   PubMed Web of Science ®Google Scholar
• MOZDZANOWSKA K, FURCHNER M, ZHARIKOVA D, FENG J, GERHARD W: Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies. J. Virol. (2005) 79:5943-5951.
   PubMed Web of Science ®Google Scholar
• JOHANSEN P, STAMOU P, TASCON RE, LOWRIE DB, STOCKINGER B: CD4 T cells guarantee optimal competitive fitness of CD8 memory T cells. Eur. J. Immunol. (2004) 34:91-97.
   PubMed Web of Science ®Google Scholar
• WAHID R, CANNON MJ, CHOW M: Virus-specific CD4+ and CD8+ cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio. J. Virol. (2005) 79:5988-5995.
   PubMed Web of Science ®Google Scholar
• PRECOPIO ML, SULLIVAN JL, WILLARD C, SOMASUNDARAN M, LUZURIAGA K: Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J. Immunol. (2003) 170:2590-2598.
   PubMed Web of Science ®Google Scholar
• CROTTY S, FELGNER P, DAVIES H, GLIDEWELL J, VILLARREAL L, AHMED R: Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. (2003) 171:4969-4973.
   PubMed Web of Science ®Google Scholar
• LUCAS M, DAY CL, WYER JR et al.: Ex vivo phenotype and frequency of influenza virus-specific CD4 memory T cells. J. Virol. (2004) 78:7284-7287.
   PubMed Web of Science ®Google Scholar
• BROWN DM, ROMAN E, SWAIN SL: CD4 T cell responses to influenza infection. Semin. Immunol. (2004) 16:171-177.
   PubMed Web of Science ®Google Scholar
• SWAIN SL, DUTTON RW, WOODLAND DL: T cell responses to influenza virus infection: effector and memory cells. Viral Immunol. (2004) 17:197-209.
   Web of Science ®Google Scholar
• AHMADZADEH M, FARBER DL: Functional plasticity of an antigen-specific memory CD4 T cell population. Proc. Natl. Acad. Sci. USA (2002) 99:11802-11807.
   Google Scholar
• SCHUMACHER R, ADAMINA M, ZURBRIGGEN R et al.: Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine (2004) 22:714-723.
   PubMed Web of Science ®Google Scholar
• SCHMITZ N, KURRER M, BACHMANN MF, KOPF M: Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J. Virol. (2005) 79:6441-6448.
   PubMed Web of Science ®Google Scholar
• VAN DER SLUIJS KF, VAN ELDEN LJ, ARENS R et al.: Enhanced viral clearance in interleukin-18 gene-deficient mice after pulmonary infection with influenza A virus. Immunology (2005) 114:112-120.
   PubMed Web of Science ®Google Scholar
• LU S, REYES VE, LEW RA et al.: Role of recurrent hydrophobic residues in catalysis of helix formation by T cell-presented peptides in the presence of lipid vesicles. J. Immunol. (1990) 145:899-904.
   PubMed Web of Science ®Google Scholar
• GHOSH P, AMAYA M, MELLINS E, WILEY DC: The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature (1995) 378:457-462.
   PubMed Web of Science ®Google Scholar
• TOULOUKIAN CE, LEITNER WW, TOPALIAN SL et al.: Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J. Immunol. (2000) 164:3535-3542.
   PubMed Web of Science ®Google Scholar
• GERLIER D, TRESCOL-BIEMONT MC, ETTOUATI L, PARIS J, RABOURDIN-COMBE C: An accessory peptide binding site with allosteric effect on the formation of peptide-MHC-II complexes? C. R. Acad. Sci. III (1998) 321:19-24.
   PubMedGoogle Scholar
• FENG MH, LAI MZ: A peptide binding weakly to the major histocompatibility molecule augments T cell responses. Eur. J. Immunol. (1994) 24:355-361.
   PubMed Web of Science ®Google Scholar
• TAMPE R, MCCONNELL HM: Kinetics of antigenic peptide binding to the class II major histocompatibility molecule I-Ad. Proc. Natl. Acad. Sci. USA (1991) 88:4661-4665.
   Google Scholar
• DE KROON AI, MCCONNELL HM: Enhancement of peptide antigen presentation by a second peptide. Proc. Natl. Acad. Sci. USA (1993) 90:8797-8801.
   Google Scholar
• DE KROON AI, MCCONNELL HM: Kinetics and specificity of peptide-MHC class II complex displacement reactions. J. Immunol. (1994) 152:609-619.
   PubMed Web of Science ®Google Scholar
• URBAN RG, CHICZ RM, STROMINGER JL: Selective release of some invariant chain-derived peptides from HLA-DR1 molecules at endosomal pH. J. Exp. Med. (1994) 180:751-755.
   PubMed Web of Science ®Google Scholar
• KROPSHOFER H, VOGT AB, STERN LJ, HAMMERLING GJ: Self-release of CLIP in peptide loading of HLA-DR molecules. Science (1995) 270:1357-1359.
   PubMed Web of Science ®Google Scholar
• STUMPTNER P, BENAROCH P: Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region. EMBO J. (1997) 16:5807-5818.
   PubMed Web of Science ®Google Scholar
• BISCHOF F, WIENHOLD W, WIRBLICH C et al.: Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes. Proc. Natl. Acad. Sci. USA (2001) 98:12168-12173.
   Google Scholar
• HESS AD, THOBURN C, CHEN W, MIURA Y, VAN DER WALL E: The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic ‘self’ epitope from a tumor-associated antigen. Clin. Immunol. (2001) 101:67-76.
   PubMed Web of Science ®Google Scholar
• HESS AD, THOBURN CJ, MIURA Y, BRIGHT EC: Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen. Clin. Immunol. (2005) 114:307-319.
   PubMed Web of Science ®Google Scholar
• FLECKENSTEIN B, JUNG G, WIESMULLER KH: Quantitative analysis of peptide-MHC class II interaction. Semin. Immunol. (1999) 11:405-416.
   PubMed Web of Science ®Google Scholar
• JOSHI RV, ZARUTSKIE JA, STERN LJ: A three-step kinetic mechanism for peptide binding to MHC class II proteins. Biochemistry (2000) 39:3751-3762.
   PubMed Web of Science ®Google Scholar
• DELCAYRE A, LE PECQ JB: Exosomes as novel therapeutic nanodevices. Curr. Opin. Mol. Ther. (2006) 8:31-38
   Web of Science ®Google Scholar
• SANDERS MT, BROWN LE, DELIYANNIS G, PEARSE MJ: ISCOM-based vaccines: the second decade. Immunol. Cell Biol. (2005) 83:119-128.
   PubMed Web of Science ®Google Scholar
• NAGATA Y, ONO S, MATSUO M et al.: Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc. Natl. Acad. Sci. USA (2002) 99:10629-10634.
   Google Scholar
• TOBIAN AA, CANADAY DH, BOOM WH, HARDING CV: Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8+ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages. J. Immunol. (2004) 172:5277-5286.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN DH, ROSENTHAL KS: The L.E.A.P.S. approach to vaccine development. Front. Biosci. (2005) 10:790-798.
   PubMed Web of Science ®Google Scholar
• FRANKE ED, HOFFMAN SL, SACCI JB JR: Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites. Vaccine (1999) 17:1201-1205.
   PubMed Web of Science ®Google Scholar
• NAGATA T, HIGASHI T, AOSHI T et al.: Immunization with plasmid DNA encoding MHC class II binding peptide/CLIP-replaced invariant chain (Ii) induces specific helper T cells in vivo: the assessment of Ii p31 and p41 isoforms as vehicles for immunization. Vaccine (2001) 20:105-114.
   PubMed Web of Science ®Google Scholar
• STEVANOVIC S, RAMMENSEE HG: Identification of T-cell epitopes using allele-specific ligand motifs. Behring Inst. Mitt. (1994):7-13.
   PubMedGoogle Scholar
• RAMMENSEE HG, FRIEDE T, STEVANOVIIC S: MHC ligands and peptide motifs: first listing. Immunogenetics (1995) 41:178-228.
   PubMed Web of Science ®Google Scholar
• HAKENBERG J, NUSSBAUM AK, SCHILD H et al.: MAPPP: MHC class I antigenic peptide processing prediction. Appl. Bioinformatics (2003) 2:155-158.
   PubMedGoogle Scholar
• KNUTSON KL, SCHIFFMAN K, CHEEVER MA, DISIS ML: Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin. Cancer Res. (2002) 8:1014-1018.
   PubMed Web of Science ®Google Scholar
• PHAN GQ, TOULOUKIAN CE, YANG JC et al.: Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J. Immunother. (2003) 26:349-356.
   Google Scholar
• BRINKMAN JA, FAUSCH SC, WEBER JS, KAST WM: Peptide-based vaccines for cancer immunotherapy. Expert Opin. Biol. Ther. (2004) 4:181-198.
   PubMed Web of Science ®Google Scholar
• HERSEY P, MENZIES SW, COVENTRY B et al.: Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol. Immunother. (2005) 54:208-218.
   PubMed Web of Science ®Google Scholar
• KALLINTERIS NL, POWELL D, BLACKWELL CE et al.: Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease. Front. Biosci. (2006) 11:46-58.
   PubMed Web of Science ®Google Scholar
• ZENG G, LI Y, EL-GAMIL M et al.: Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. (2002) 62:3630-3635.
   PubMed Web of Science ®Google Scholar
• SUNDARAM R, SUN Y, WALKER CM, LEMONNIER FA, JACOBSON S, KAUMAYA PT: A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design. Vaccine (2003) 21:2767-2781.
   PubMed Web of Science ®Google Scholar
• LETVIN NL, MONTEFIORI DC, YASUTOMI Y et al.: Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc. Natl. Acad. Sci. USA (1997) 94:9378-9383.
   Google Scholar
• ALLEN TM, VOGEL TU, FULLER DH et al.: Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol. (2000) 164:4968-4978.
   PubMed Web of Science ®Google Scholar
• DEVITO C, ZUBER B, SCHRODER U et al.: Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J. Immunol. (2004) 173:7078-7089.
   PubMed Web of Science ®Google Scholar
• GERLACH JT, DIEPOLDER HM, JUNG MC et al.: Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology (1999) 117:933-941.
   PubMed Web of Science ®Google Scholar